Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
British Journal of Cancer|September 1, 1996
How should cancer presenting as a malignant pleural effusion be managed?H Bonnefoi, I E Smith
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2010
A review of PARP inhibitors: from bench to bedsideC Underhill, M Toulmonde, H Bonnefoi
Revue Medicale Suisse|March 16, 2007
[What's new in gynecology in 2006?]P Petignat, A-T Vlastos, H Bonnefoi, et al.
Bulletin Du Cancer|July 8, 2010
[Biomarkers of endocrine therapy-resistance in breast cancers]P de Cremoux, M Debled, H Bonnefoi, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 26, 2006
Yolk sac tumours of the ovary: an updateP Dällenbach, H Bonnefoi, M-F Pelte, et al.
International Journal of Radiation Oncology, Biology, Physics|June 2, 1998
Effect of low-dose chest irradiation before chemotherapy on the rate of local failure in small-cell lung cancerP Hösli, H Bonnefoi, R O Mirimanoff, et al.
Breast Cancer Research and Treatment|January 5, 2002
An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancerH Bonnefoi, L Biganzoli, T Cufer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2000
Phase II trial of up-front accelerated thoracic radiotherapy combined with chemotherapy and optional up-front prophylactic cranial irradiation in limited small-cell lung cancer. Groupe d'Oncologie Thoracique des Régions AlpinesA Hügli, D Moro, B Mermillod, et al.
European Journal of Cancer (Oxford, England : 1990)|January 13, 2015
Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-study of EORTC 10994/BIG 1-00 phase III trialF Fei, C Messina, L Slaets, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2003
An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancerH Bonnefoi, L Biganzoli, L Mauriac, et al.
Pageof 5